Complementary roles of surgery and systemic treatment in clear cell renal cell carcinoma

A Ingels, R Campi, U Capitanio, D Amparore… - Nature Reviews …, 2022 - nature.com
Standard-of-care management of renal cell carcinoma (RCC) indisputably relies on surgery
for low-risk localized tumours and systemic treatment for poor-prognosis metastatic disease …

First-line treatments for metastatic clear cell renal cell carcinoma: an ever-enlarging landscape

S Gulati, C Labaki, GS Karachaliou, TK Choueiri… - The …, 2022 - academic.oup.com
Abstract Treatment paradigm for metastatic clear cell renal cell carcinoma (mccRCC) has
changed dramatically over the recent decades. From cytokines, interleukin-2 and interferon …

The role of cytoreductive nephrectomy in metastatic renal cell carcinoma: a real-world multi-institutional analysis

P Ghatalia, EA Handorf, DM Geynisman… - The Journal of …, 2022 - auajournals.org
Purpose: The role of cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma
(mRCC) was challenged by the results of the CARMENA trial. Here we evaluate the role of …

Pathological outcomes of patients with advanced renal cell carcinoma who receive nephrectomy following immunotherapy

J Panian, A Saidian, K Hakimi, A Ajmera… - The …, 2024 - academic.oup.com
Background Even though cytoreductive nephrectomy (CN) was once the standard of care for
patients with advanced renal cell carcinoma (RCC), its role in treatment has not been well …

[HTML][HTML] Current role of cytoreductive nephrectomy in metastatic renal cell carcinoma

C Van Praet, C Slots, N Vasdev, S Rottey… - Turkish Journal of …, 2021 - ncbi.nlm.nih.gov
Historically, immediate cytoreductive nephrectomy (CN) was considered the standard of
care in patients with metastatic renal cell carcinoma (mRCC) who were fit enough to …

Impact of previous nephrectomy on clinical outcome of metastatic renal carcinoma treated with immune-oncology: a real-world study on behalf of Meet-URO Group …

M Stellato, D Santini, E Verzoni, U De Giorgi… - Frontiers in …, 2021 - frontiersin.org
Background Immune-Oncology (IO) improves Overall Survival (OS) in metastatic Renal Cell
Carcinoma (mRCC). The prognostic impact of previous Cytoreductive Nephrectomy (CN) …

Impact of cytoreductive nephrectomy prior to combination therapy of ipilimumab plus nivolumab in metastatic renal cell carcinoma

T Hara, J Furukawa, Y Shiraishi… - … Journal of Urology, 2023 - Wiley Online Library
Objectives The efficacy of cytoreductive nephrectomy (CN) for metastatic renal cell
carcinoma (mRCC) treated with immune checkpoint inhibitors (ICIs) has been suggested in …

[HTML][HTML] Stereotactic body radiation therapy to the kidney for metastatic renal cell carcinoma: A narrative review of an emerging concept

C Hao, J Liu, C Ladbury, T Dorff, S Sampath… - Cancer Treatment and …, 2023 - Elsevier
This narrative review provides a historical overview of cytoreductive nephrectomy for
metastatic renal cell carcinoma (mRCC) and examines the safety and therapeutic potential …

Cytoreductive nephrectomy following immunotherapy-base treatment in metastatic renal cell carcinoma: a case series and review of current literature

SJ Dawsey, SC Campbell, MC Ornstein - Current Oncology, 2021 - mdpi.com
The role and timing of cytoreductive nephrectomy in patients with metastatic renal cell
carcinoma receiving immunotherapy-based regimens is unclear. However, the ability to …

Three years after CARMENA: what have we learned?

E Roussel, B Beuselinck, M Albersen - European Urology, 2021 - europepmc.org
Cytoreductive nephrectomy makes way for more effective systemic treatments in the current
mRCC treatment paradigm, as disease volume and the number of IMDC risk factors …